Table 3. The association between clinical characteristics and treatment outcome in EOC patients treated with platinum-based chemotherapy.
| Characteristics | Recurrence | P value | Survival | P value | ||
|---|---|---|---|---|---|---|
| HR | 95% CIa | HR | 95% CIa | |||
| Age | ||||||
| <50 vs. ≥50 years | 1.06 | 0.64–1.77 | 0.820 | 1.23 | 0.73–2.10 | 0.440 |
| FIGO stage | ||||||
| I–II vs. III–IV | 9.99 | 1.93–35.05 | 0.024 | 9.66 | 1.73–40.05 | 0.026 |
| Grade | ||||||
| G1–2 vs. G3 | 5.29 | 1.73–17.05 | 0.013 | 7.40 | 0.20–14.80 | 0.019 |
| Tumor residual size | ||||||
| 0 vs. ≤1 cm | 4.39 | 1.75–10.93 | 0.011 | 5.40 | 0.20–11.80 | 0.017 |
| 0 vs. >1 cm | 3.09 | 1.05–7.93 | <0.01 | 3.40 | 1.20–6.80 | <0.01 |
| HSP70 expression | ||||||
| Low vs. high | 1.48 | 1.27–2.33 | 0.014 | 1.62 | 1.31–2.31 | 0.023 |
a, adjusted for age, stage, grade, tumor residue, and MGRN1 expression. EOC, epithelial ovarian cancer.